



## Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 26, 2023

MALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that a prespecified analysis from the Phase 3 ROMAN trial detailing one-year reductions in cisplatin-related chronic kidney disease in patients with head and neck cancer treated with avasopasem will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023, in Chicago, IL.

### Presentation Details:

**Title:** One-year reductions in cisplatin-related chronic kidney disease (CKD) in patients with head and neck (HNC) cancer treated with avasopasem manganese: A prespecified analysis from the phase 3 ROMAN trial

**Abstract Number:** 6066

**Session Title:** Head and Neck Cancer

**Session Date and Time:** Monday, June 5, 2023, 1:15 PM – 4:15 PM ET

The titles of the abstracts are currently available in the [ASCO digital program](#), with the full abstracts scheduled to be published on May 25, 2023, at 5 p.m. ET. The presentation will be available on Galera's website at the start of the poster session at <https://www.galeratx.com/our-pipeline/key-publications>.

### **About Galera Therapeutics**

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer. Galera's selective dismutase mimetic product candidate avasopasem manganese (avasopasem, or GC4419) is being developed for radiation-induced toxicities. A New Drug Application (NDA) for avasopasem is currently under priority review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee (PDUFA) date of August 9, 2023 for radiotherapy-induced severe oral mucositis in patients with head and neck cancer undergoing standard-of-care treatment. The Company's second product candidate, rucosopasem manganese (rucosopasem, or GC4711), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Galera is headquartered in Malvern, PA.

### **Investor Contacts:**

Christopher Degnan  
Galera Therapeutics, Inc.  
610-725-1500  
[cdegnan@galeratx.com](mailto:cdegnan@galeratx.com)

William Windham  
Solebury Strategic Communications  
646-378-2946  
[wwindham@soleburystat.com](mailto:wwindham@soleburystat.com)

### **Media Contact:**

Zara Lockshin  
Solebury Strategic Communications  
330-417-6250  
[zlockshin@soleburystat.com](mailto:zlockshin@soleburystat.com)